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In the UK, life extending, end-of-life (EoL) treatments are an exception to standard cost-per-
quality-adjusted life year (QALY) thresholds. This implies that greater value is placed on 
gaining these QALYs, than QALYs gained by the majority of other patient groups treated for 
anything else in the health system, even for other EoL contexts (such as quality of life (QoL) 
improvements alone). This paper reports a Person Trade-Off (PTO) study to test whether 
studies that find societal support for prioritising EoL life extensions can be explained by the 
severity, in terms of prospective QALYs loss, of the non-terminal comparator scenarios.  
 
Eight health scenarios were designed depicting i) QoL improvements for non-EoL temporary 
(T-QoL) and chronic (C-QoL) health problems and ii) QoL improvements and life extensions 
(LEs) for EoL health problems. Preferences were elicited from a quota sample of 901 Scottish 
respondents in 2016 using PTO techniques via Computer Assisted Personal Interview (CAPI).  
 
Our results indicate that there is little evidence to suggest that the severity of non-EoL 
comparator scenarios influence preferences for EoL treatments. Respondents do not appear 
to have a preference for EoL over non-EoL health gains; instead there is some indication that 
non-EoL health gains are preferred, particularly when compared to EoL-LE health gains. 
Comparing between QoL and life extending EoL scenarios, our results suggest QoL 
improvements are preferred to life extensions. Overall, results challenge current UK EoL 
policy which gives additional weight to EoL health gains, particularly EoL life extensions in 
the case of the National Institute for Health and Care Excellence (NICE).  
Keywords 
 




Health Technology Assessment (HTA) agencies typically consider the cost per quality-
adjusted life year (QALY) of new technologies, compared to existing technologies, against a 
threshold. In the UK, this threshold is £20,000-£30,000 per QALY, above which treatments 
are unlikely to be recommended for provision (NICE, 2013). However, since the introduction 
of cost-per-QALY thresholds, there has been debate about whether a QALY is a QALY is a 
QALY (Baker et al., 2010; Donaldson et al., 1988). Some exceptions to the standard 
threshold now exist, for example, in 2009 the National Institute for Health and Care 
Excellence (NICE) introduced supplementary guidance that gave special consideration to 
life-extending, end-of-life (EoL) treatments (NICE, 2009). In England, a threshold of £50,000 
per QALY has emerged for these treatments (Dillon & Landells, 2018). This implies that 
greater value is placed on gaining these QALYs, than QALYs gained by the majority of other 
patient groups treated for anything else in the health system, even for other EoL contexts 
(such as quality of life (QoL) improvement alone). The focus of this paper is whether studies 
that find societal support for prioritising EoL life extensions can be explained by a specific 
severity concern, prospective QALY loss, which may also apply to other groups and 
interventions. Given policy priority for such specific QALY gains, the key empirical question 
becomes whether this has been established through comparison with less-severe patient 
scenarios and, thus, the extent to which the severity of non-terminal comparator scenarios 






1.1.1. Empirical evidence 
 
Influencing the case for NICE’s EoL policy was the claim that society places special value on 
these types of health gains (Rawlins et al., 2010). However, this claim was not based on 
evidence and a recent review of twenty-three empirical studies has found that evidence is 
equivocal; eight studies reported results suggesting a positive premium for EoL, eleven 
negative and four report mixed findings (Shah et al., 2018). While the majority of methods 
used could be categorised as either choice or matching a variety of approaches are utilised, 
for example: discrete choice experiments (DCEs) (Rowen et al., 2016; Shah et al., 2015; 
Skedgel et al., 2015), budget allocation (Linley & Hughes, 2013), person trade-off (PTO) 
(Pinto-Prades et al., 2014) and willingness to pay (WTP) (Pennington et al., 2015; Pinto-
Prades et al., 2014; Shiroiwa et al., 2013). These approaches have different theoretical 
underpinnings (e.g. welfare economics (WTP) and consumer theory (DCEs)), use different 
framings (e.g. people (PTO) and pounds (WTP)) and are answered from different 
perspectives (e.g. individual (WTP) and social (PTO and budget allocation)). Despite the 
variation in methods and study design, in general, respondents express a value for EoL 
treatment scenarios and (a range of) non-EoL alternative treatment scenarios. Comparing 
these values allows examination of relative values. Thus the design of the alternative 
scenarios (the comparators) is crucial as respondents’ relative values may depend on those 
alternatives. For example, the relative value of ‘X’ could be dependent on whether the 
comparator is ‘Y’ or ‘Z’ or something else. If ‘X’ is three months life extension for terminally 
ill patients, its value might be different when compared to a QoL gain for patients with a 
temporary health condition in relatively good health (‘Y’) than a similar QoL health gain but 
to patients in very poor health (‘Z’). Thus the severity of the non-EoL comparator scenario(s) 
might explain relative societal values of EoL QALYs. This is important as NICE EoL policy does 
not distinguish between different types of QALYs; life-extending, EoL QALYs are, in effect, 
more valued than the vast majority of other QALY types. So in considering the relative value 
of a QALY a necessary question is “. . . in comparison to what?” 
 
1.1.2. The importance of comparators   
 
Within studies that did not find an EoL premium, the non-EoL comparators used in Linley 
and Hughes (2013) and Shah et al. (2015) are the most severe in terms of prognosis. Linley 
and Hughes (2013) set-out a choice between providing a treatment that extends life by six 
months for a disease that leads to death in 18 months (EoL) or in 60 months (non-EoL) 
without treatment. Likewise, in the DCE of Shah et al. (2015), life expectancies without 
treatment for EoL scenarios are three months, one year or two years compared to only 
three or five years for non-EoL scenarios. An issue with these comparators is that life 
expectancies are so poor that respondents may have interpreted all scenarios as being EoL. 
Interestingly, in a DCE where the non-EoL life expectancies are larger (five, ten, thirty and 
sixty years), and consequently the ‘comparator’ situation is less severe, a positive EoL 
premium is found (Rowen et al., 2016). 
 
The potential influence of less severe comparators on relative values is best illustrated in 
Shiroiwa et al. (2013), Pennington et al. (2015) and Pinto Prades et al. (2014). These three 
studies use temporary health problems in which current or normal health (100%) is returned 
to following a period of illness; the size of the QALY health gains were also the same for EoL 
and non-EoL within each of these respective studies. While Pennington et al. (2015) and 
Pinto-Prades et al. (2014) find an EoL premium, Shiroiwa et al. (2013) find mixed results. The 
non-EoL comparators in Shiroiwa et al. (2013) feature mild, moderate and severe temporary 
health states; severity is defined in terms of QoL at the onset of illness. EoL-LE scenarios 
featured a life extension (LE) for a severe initial QoL health state and a life extension in 
perfect health for a life-threatening situation (an initial health state was not provided). 
Although average WTP per QALY values were higher for health gains for EoL health states 
than for mild temporary conditions, in general, treatments for moderate and severe 
temporary health states received higher average WTP per QALY values. These results 
suggest severity in terms of prospective QALY loss may not influence values as average WTP 
per QALY values were higher for non-EoL scenarios when the same onset QoL health state – 
severe – was used in both non-EoL and EoL scenarios. However, these relative values are 
across rather than within sample as respondents were only asked their WTP for one 
scenario. Also the EoL life expectancy untreated was only one month and treatment would 
have extended their life in a severe health state. This poor prognosis compared to treatment 
for non-EoL scenarios resulting in immediate recovery may also explain these findings.   
 
In Pennington et al. (2015) non-EoL scenarios included a 25% QoL loss over four years; a 
10% QoL loss over ten years; and time spent in a coma and in Pinto-Prades et al. (2014) the 
patient had 30% health for six or 18 months with an initial treatment. The EoL premium 
found in both studies could be because comparators are depicted as mild conditions in 
which patients will recover with no lasting effects, for example, after a period in a coma 
respondents’ are told they will return to their current health and “pick up where you left 
off” (Pennington et al., 2015, p284). Also neither study explored the effect of severity in 
terms of prospective QALY loss. Indeed, no EoL study has yet designed and introduced a 
chronic scenario in which the patient does not return to full health (or better health) 
following the treatment period but instead remains in a state of worse health, than at the 
point of diagnosis, for the foreseeable future. In terms of prospective QALY loss the EoL 
scenario would still be the most severe case but a severity gradient would be created 
whereby the order of severity is: EoL > chronic > temporary. This would enable examination 
of whether the severity of non-EoL comparator scenarios might explain relative societal 
values of such life-extending EoL QALYs.  
 
Pinto-Prades et al. (2014) is also only one of a handful of studies to examine the relative 
value of health gains between EoL scenarios. This is important as NICE EoL policy does 
distinguish between types of EoL health gains; only life extensions are prioritised. This policy 
is contradicted by the limited available evidence as four of five studies indicate that quality 
of life improvements within EoL may be more preferred (Hansen and Kjær, 2019; McHugh et 
al., 2018; Pinto-Prades et al., 2014; Shah et al., 2014); only Shah et al. (2015) found a 
preference for life extensions. However, no study has yet examined preferences for 
different compositions of life extensions at the EoL i.e. a longer life extension in a lower QoL 
versus a shorter life extension in a higher QoL. 
 
The aim of this study is to test how the severity of the non-EoL comparator scenario affects 
the relative value of EoL QALYs and to examine the relative value of different types of QALYs 
gained at the EoL. We do this by building on Pinto-Prades et al. (2014) through the 
introduction of new scenarios, eliciting preferences using the PTO approach. From a 
normative standpoint this approach better reflects the questions under consideration as it is 
‘other focused’ and takes a social decision maker perspective. In summary, this paper will 
focus on the following research questions which have different degrees of novelty: 
 
1. Are preferences for EoL treatments contingent upon the severity of the non-EoL 
comparator? For EoL treatments that: 
a. extend life (EoL-LE) 
b. improve quality of life (EoL-QoL) 
These questions have not been addressed formally in the literature. 
  
2. Are preferences for EoL treatments contingent upon the type of health gain i.e. life 
extension versus quality of life?  
There is very limited evidence about this issue (Hansen and Kjær, 2019; McHugh et 
al., 2018; Pinto-Prades et al., 2014; Shah et al., 2015; Shah et al., 2014). 
 
In the next section we present a survey aimed at addressing these questions.   
 
2. Methods  
 
2.1.  Scenarios 
 
The survey was based on eight scenarios (see Table 1) designed to enable comparisons 
which respond to the above research questions. In all cases, participants had to choose 
between treatments that provide exactly the same health gain (0.5 QALYs) for different 
health problems: terminal (EoL) conditions, a chronic (C) health problem and a temporary 
(T) health problem. Two of the eight scenarios in Table 1 can be considered as benchmark 
scenarios (S7-S8). These scenarios represent cases that NICE EoL Guidance gives special 
value to i.e. short life extensions to those with a terminal illness (EoL-LE). (Relatively) small 
health gains (0.5 QALYs) were used, which reflects the (upper end) of the QALY gains 
considered through the EoL policy. Different life expectancy and QoL combinations of the 
0.5 QALY gain were also used in these two scenarios to allow for a new way to explore the 
relative value of health gains within EoL: a one-year life expectancy gain at 50% QoL (S7) and 
a seven months’ life expectancy gain at 80% QoL (S8). In the other six comparator scenarios 
(S1-S6) the 0.5 QALY gain was achieved by improving QoL by 50% for a period of one year; 
QoL at the point of treatment was either 30% or 50% meaning QoL improved to either 80% 
or 100%. QoL was depicted on a scale from Dead to 100% (full health) and EQ-5D-5L 
(Herdman et al., 2011) descriptions were used to illustrate how the QoL percentages – 80%, 
50% and 30% – in the scenarios could be described. Since all scenarios presented to 
participants were interpreted as better than death, in terms of prospective QALY loss, the 
terminal case is the most severe health problem and the chronic condition is more severe 









Table 1 – Scenario Descriptions 
Scenario Descriptions 




Current Treatment New treatment QoL 
After 
Illness 




















100% 50% 1 year 100% 1 year Death   50% / 1 
year 
0.5 
3 T-QoL 100% 30% 1 year 80% 1 year 100%   50% / 1 
year 
0.5 
4 C-QoL 100% 30% 1 year 80% 1 year 30%   50% / 1 
year 
0.5 
5 T-QoL 100% 50% 1 year 100% 1 year 100%   50% / 1 
year 
0.5 
6 C-QoL 100% 50% 1 year 100% 1 year 50%   50% / 1 
year 
0.5 




50% 1 year Death   50% / 1 
year 
0.5 




80% 7 months Death   80% / 7 
mths 
0.47 
* Quality of life (QoL) and life extending (LE) improvements for end of life (EoL) health problems (EoL-QoL and 
EoL-LE). QoL improvements for Non-EoL temporary (T-QoL) and chronic (C-QoL) health problems. 
 
Scenarios were presented diagrammatically (Figure 1). The vertical axis represents QoL and 
the horizontal axis shows time. Prognosis untreated is shown by the (solid) purple line and 
the blue dashed line shows the effect of treatment (i.e. health gain). Diagrams were 
explained to respondents by animating lines on the graph in turn with corresponding text 

















2.2.  Elicitation procedure 
 
PTO questions are typically used to elicit societal (or citizens’) preferences (Nord, 1995). In 
our study respondents were asked to imagine a situation in which the NHS has a fixed, 
additional budget and two new treatments are available (A and B) each of which can treat 
100 patients (see Appendix 2). Only one treatment can be chosen. Respondents took the 
role of societal decision maker and were asked which treatment should be provided 
(respondents were not a patient in this scenario). The number of patients in the most 
preferred group was then altered using a bi-section approach. For example, if A was 
preferred the next question was 50A vs. 100B this continued until a point of indifference 
was reached signifying equivalence between the two groups. This indicates the relative 





2.3.  Structure of survey  
 
The survey (see Table 2) was split into 6 versions (V1A-3B).  V1A-1B focused on EoL-LE vs. 
non-EoL health problems, V2A-2B focused on EoL-QoL vs. non EoL health problems and V3A-
3B focused on different types of EoL health gains. Versions contain different framings of the 
same scenario, for example, S7 (V1A) and S8 (V1B) are both EoL-LE scenarios representing a 
0.5 QALY gain but are comprised of different QoL and life extensions (see Table 1).  
Preferences were elicited using PTO, WTP and Benefit Trade-Off (BTO) techniques. This 
paper focuses on the analysis of PTO data only; findings from the other approaches will be 
reported separately. The questionnaire concluded with socio-demographic questions. 
Appendix 3 shows the script used in the introductory animation and Appendix 2 details the 
text of the PTO questions. 
 
The structure of the survey is shown in Table 2. Respondents were presented with an 
information sheet about the study and given the opportunity to ask questions before 
providing informed consent. Initial socio-demographic questions were asked to assess if 
respondents met the quota criteria (see ‘Piloting and Data Collection’). A short, animated 
video then introduced the context and premise of the study.  The video describes, in simple 
terms, the issues of scarcity and opportunity cost within the NHS and the need to make 
decisions about the provision of treatments and services. It explains that many different 
things could be considered when making decisions about how best to allocate resources, 
such as severity of illness or quality of life or life extension, and that it is important to know 
the views of the general public (see Appendix 3 for the script). Block 1 concluded with an 
explanation of the health scenarios explained using examples (see Figure 1). The order of 
Blocks 2-4 were randomised and the questions within these blocks were randomised. The 
survey finished with a number of socio-demographic questions (Block 5).  
 
Table 2 – Survey Design 
Version (V) 1A 1B 2A 2B 3A 3B 
Block 1 
(Introduction) 
Initial quota demographics 
Introduction and Video 
Health Diagram Explanation 
Block 2 (PTO) 
A: EoL-LE vs.  
T-QoL  




(S8 vs. S5) 
E: EoL-QoL 
vs. T-QoL  
(S1 vs. S3) 
F: EoL-QoL 
vs. T-QoL  
(S2 vs. S5) 
K: EoL-LE 
vs. EoL-QoL  




(S7 vs. S1) 
C: EoL-LE vs. 
 C-QoL 





vs. C-QoL  
(S1 vs. S4) 
H: EoL-QoL 
vs. C-QoL  
(S2 vs. S6) 
L: EoL-LE vs. 
EoL-LE 
 (S7 vs. S8) 
L: EoL-LE vs.  
EoL-LE  









2.4.  Addressing the Research Questions (RQs) 
 
Using this survey design, the RQs presented in the introduction were addressed as follows:  
 
1. Are preferences for EoL treatments contingent upon the severity of the non-EoL 
comparator? For EoL treatments that: 
a. extend life (EoL-LE) 
b. improve quality of life (EoL-QoL) 
These questions are responded to using the following comparisons from V1A-2B in 
Table 2:  
(S8 vs. S6) 
I: T-QoL vs.  
C-QoL  
(S3 vs. S4) 
J: T-QoL vs. 
 C-QoL  
(S5 vs. S6) 
I: T-QoL vs.  
C-QoL  
(S3 vs. S4) 
J: T-QoL vs. 
 C-QoL  
(S5 vs. S6) 
Block 3 WTP WTP responses are not reported here 




 EoL-LE vs. T-QoL: PTOs A and B 
 EoL-LE vs. C-QoL: PTOs C and D  
 EoL-QoL vs. T-Qol: PTOs E and F  
 EoL-QoL vs. C-QoL: PTOs G and H  
 
Previous literature (see Pinto-Prades et al. (2014)) indicates that EoL-LE and EoL-QoL may be 
prioritised when compared to T-QoL given the severity of the terminal condition. However, 
preferences for EoL-LE could vanish or be attenuated when C-QoL is the comparator as this 
condition is more severe than T-QoL.   
 
2. Are preferences for EoL treatments contingent upon the type of health gain i.e. life 
extension versus quality of life? This is responded to in two different ways: 
a. Between-subject comparisons: V1A-2B responses to T-QoL and C-QoL, 
respectively, are compared to EoL-LE and EoL-QoL: 
i. T-QoL vs. EoL-LE and EoL-QoL: PTOs A and E; and PTOs B and F 
ii. C-QoL vs. EoL-LE and EoL-QoL: PTOs C and G; and PTOs D and H 
b. Within-subject comparisons: using V3A-3B the following comparisons are 
made: 
i. EoL-LE vs. EoL-QoL: PTO K 
ii. EoL-LE vs. EoL-LE: PTO L 
 
In V3A-3B there are two different framings of EoL-LE: in S7 a 0.5 QALY gain is achieved with 
a smaller gain in QoL (50%) and a larger life expectancy gain (one year) than in S8 (80% QoL 
gain for seven months’ life expectancy gain). This comparison is new in the literature and 
provides a different way to examine preferences for health gains within EoL. 
 
2.5.  Piloting and Data Collection 
 
The survey was programmed and administered by Accent (http://www.accent-mr.com/) and 
delivered via Computer Assisted Personal Interview (CAPI) by trained interviewers.  
 
Prior to programming, survey questions were piloted via in-depth, one-on-one, interviews 
by the project team with members of the Scottish general public (n=60) to test the 
interpretation and design of the scenarios. In addition, further face-to-face piloting with a 
convenience sample of university colleagues focused on the design and wording of survey 
questions on the CAPI device. Minor modifications were made to the presentation, and the 
total number of questions asked in each version was altered to enable completion of the 
survey, on average, in less than 30 minutes.     
  
Respondents were quota sampled across Scotland on basis of age, gender, employment 
status and location (rural/urban). Questions were administered in respondents’ homes and 
a £5 voucher was offered as an incentive.  
 
2.6.  Data Analysis  
 
In general, data analysis focuses on individual PTO pairings within each version of the 
survey. Only data across different versions of the survey which correspond to the same 
scenario pairing were pooled and analysed together. For example, PTO I: S3 vs. S4 (T-QoL vs. 
C-QoL) data were pooled from V1A and V2A.  
 
2.6.1. PTO data 
 
Respondents’ relative preference between patient groups are indicated through calculation 
of PTO ratios – ‘median of ratios’ and the ‘ratio of means’ (see Appendix 4 for details and 
illustrative calculations). While there is no single, correct approach for aggregating PTO 
ratios, there is consensus that – calculating the ‘mean of ratios’ – should be avoided as this 
ratio is affected by outliers (Baker et al., 2010; Chilton et al., 2002; Pinto-Prades et al., 
2014). A PTO ratio of 1 indicates that respondents are indifferent between the two 
treatments and a ratio >1 indicates that more patients need to receive the less preferred 
treatment to produce the same benefit as 1 patient receiving the more preferred treatment. 
Strength of preference is examined in two additional ways. The average point of 
indifference for participants who prefer treatment X  is compared to the average point of 
indifference for participants who prefer treatment Y i.e. No.X(mean)=100Y vs. 
100X=No.Y(mean); the lower the mean point of indifference, the stronger the strength of 
preference. ‘Extreme’ preferences are defined as responses where 1 patient receiving the 
most preferred treatment is valued as equivalent to 100 patients receiving the least 
preferred treatment. Additionally, 95% confidence intervals (CI) and chi-square tests are 
calculated for respondents’ initial binary choice between A and B.  
 
2.7.  Research Ethics  
 
Ethical approval for this study was obtained from the Glasgow School for Business and 






Data were collected in two waves: May to June 2016 and September to October 2016 (the 
research team deemed time stamps of 206 surveys in the first wave as too short (completed 
in <13 minutes) so new data was collected (the second wave)). In total 901 respondents 
completed the survey, nationally representative of Scotland with respect to age, gender, 
employment status and location; versions were broadly comparable (see Table 3).    
Table 3 – Socio-demographic characteristics: versions and total sample 
 
Variables Version Total Scotland^ 
1A 1B 2A 2B 3A 3B 
n % n % n % n % n % n % n % % 
Gender   
Male 79 54% 55 37% 67 45% 84 53% 65 45% 84 56% 434 48% 48% 
Female 68 46% 95 63% 82 55% 76 48% 80 55% 66 44% 467 52% 52% 
Age    
18-30 26 18% 26 17% 31 21% 41 26% 32 22% 32 21% 188 21% 21% 
31-50 51 35% 54 36% 55 37% 56 35% 51 35% 52 35% 319 35% 35% 
51-64 39 27% 35 23% 33 22% 35 22% 26 18% 39 26% 207 23% 23% 
65-74 17 12% 19 13% 12 8% 18 11% 21 14% 18 12% 105 12% 21% 
75+ 14 10% 16 11% 18 12% 10 6% 15 10% 9 6% 82 9% 
Area   
Urban 119 81% 115 77% 127 85% 138 86% 114 79% 127 85% 740 82% 82% 
Rural 28 19% 35 23% 22 15% 22 14% 31 21% 23 15% 161 18% 18% 
Employment                 
Employed 81 55% 70 47% 90 60% 104 65% 79 54% 100 67% 524 58% 60% 
Unwaged 30 20% 41 27% 24 16% 32 20% 28 19% 21 14% 176 20% 20% 
Retired 36 24% 39 26% 35 23% 24 15% 37 26% 29 19% 200 22% 20% 
Household income   
Low (less than £20,800) 58 39% 70 47% 72 48% 60 38% 62 43% 52 35% 374 42% 37% 
Middle (£20,800 - £51,999) 37 25% 46 31% 38 26% 56 35% 42 29% 56 37% 275 31% 42% 
High (more than £51,999) 32 22% 13 9% 9 6% 17 11% 11 8% 12 8% 94 10% 20% 
Education   
Low (up to GCSE) 38 26% 69 46% 55 37% 46 29% 51 35% 42 28% 301 33% 50% 
Midde (Highers & Further 
Education) 
75 51% 56 38% 79 54% 87 54% 67 47% 75 50% 439 49% 24% 
High (University) 32 22% 23 15% 13 9% 25 16% 22 15% 26 17% 141 16% 26% 
Marital Status   
Single/Never married 49 33% 52 35% 42 28% 44 28% 41 28% 41 27% 269 30% 28% 
Married/ Living with partner/ 
Civil partnership 
71 48% 62 41% 71 48% 84 53% 65 45% 78 52% 431 48% 42% 
Divorced/Separated 12 8% 20 13% 20 13% 17 11% 21 14% 19 13% 109 12% 17% 
Widowed 14 10% 15 10% 15 10% 15 9% 18 12% 10 7% 87 10% 13% 
Ethnicity   
White 140 95% 147 98% 144 97% 157 98% 141 97% 146 97% 875 97% 96% 
BME/other 7 5% 2 1% 3 2% 3 2% 2 1% 4 3% 21 2% 4% 
Religion   
Catholic 17 12% 28 19% 40 27% 29 18% 25 17% 29 19% 168 19% 17% 
Church of Scotland 42 29% 39 26% 35 23% 44 28% 47 32% 41 27% 248 28% 34% 
Other Christian 19 13% 22 15% 9 6% 6 4% 7 5% 7 5% 70 8% 6% 
Other religions 10 7% 1 1% 2 1% 2 1% 2 1% 4 3% 21 2% 3% 
No religion 57 39% 51 34% 57 38% 71 44% 60 41% 64 43% 360 40% 39% 
n 147 150 149 160 145 150 901  
Note. NB: For some questions there was an option to answer “do not know”, “prefer not to say” or “other”, these responses are not included in the table and may affect 




Table 4 – PTO Results: preferences for EoL vs. non-EoL health gains  
PTO A B C D E F G H 
Version  1A 1B 1A 1B 2A 2B 2A 2B 
Scenario Type 
(X vs Y) 
EoL-LE vs. T-QoL  EoL-LE vs. C-QoL  EoL-QoL vs. T-QoL  EoL-QoL vs. C-QoL  
X (Scenario)  
vs.  
Y (Scenario) 
50%/1yr (S7)  
vs.                          
30-80%/1yr (S3) 
80%/7mths (S8) 
vs.                          
50-100%/1yr (S5) 
50%/1yr (S7)  
vs.                                               
30-80%/1yr (S4) 
80%/7mths (S8)  
vs.                           
50-100%/1yr (S6) 
30-80%/1yr (S1) 
vs.                              
30-80%/1yr (S3) 
50-100%/1yr (S2)  
vs.                          
50-100%/1yr (S5) 
30-80%/1yr (S1) 
vs.                                      
30-80%/1yr (S4) 
50-100%/1yr (S2) 




















No.X (Mean) = 
100Y 

































58% 53% 51% 42% 59% 62% 55% 54% 
Median of 
ratios (X:Y)^ 
2.11 5.08 1.03 2.35 1 1.82 1 2.11 
Ratio of 
Means (X:Y)^ 
1.48 1.81 1.15 1.73 1.06 1.25 1.10 1.37 
Total 147 150 147 150 149 160 149 160 
+
These percentages show the proportion of respondents with extreme preferences among those who favoured Treatment X or Treatment Y. ^These ratios represent the 
number of patients that have to receive Treatment X to produce the same benefit as one patient receiving Treatment Y. ***1% significance level; **5% significance level; 
*10% significance level. 
 
Table 5 - PTO Results: preferences within non-EoL and within EoL health gains  
PTO I J K L 
Version  1A-2A 1B-2B 3A-3B 3A-3B 
Scenario Type 
X vs Y 
C-QoL vs. T-QoL EoL-LE vs. EoL-QoL  EoL-LE vs. EoL-LE  




vs.                             
30-80%/1yr (S3) 
50-100%/1yr (S6) 
vs.                              
50-100%/1yr (S5) 
50%/1yr (S7)        
vs.                                 
30-80%/1yr (S1) 
50%/1yr (S7)      












No. X (Mean)=100Y 32 28 33 42 















100X=No.Y (Mean) 21 25 35 36 




52% 43% 37% 33% 
Median of ratios (X:Y)^ 1.6 1.9 1.6 1.14 
Ratio of Means (X:Y)^ 1.26 1.28 1.41 1.12 
Total 296 310 295 295 
+
These percentages show the proportion of respondents with extreme preferences among those who favoured 
Treatment X or Treatment Y. ^These ratios represent the number of patients that have to receive Treatment X 
to produce the same benefit as one patient receiving Treatment Y. ***1% significance level; **5% significance 
level; *10% significance level. 
 
 
3.2 Are preferences for EoL treatments contingent upon the severity of the non-EoL 
comparator?   
 
Overall, there is little evidence that the severity of non-EoL comparator scenarios influence 
preferences (see Tables 4 and 5). These results indicate that respondents do not have a 
preference for EoL over Non-EoL health gains (see PTOs A-H). Instead Non-EoL health gains 
are preferred in the majority of cases; the results of PTOs A, B, D and H are statistically 
significant (see Table 4). This is in contrast to what is expected according to severity based 
on prospective QALY loss: aggregating across PTOs (A-H), approximately 59% of respondents 
prefer non-EoL treatments to EoL-LE treatments. Across PTOs A-D, within-subject 
comparisons indicate that the severity of the comparators does not influence preferences 
for EoL-LE treatments. For example, comparing PTOs A and C suggests respondents have a 
higher preference for T-QoL than C-QoL when the comparator in both cases is EoL-LE (S7); 
support for EoL-LE decreases by 9% when T-QoL is the comparator and this finding is 
statistically significant. In relation to preferences for EoL-QoL (PTOs E-G), a within-subject 
comparison indicates severity may play a role. 61% of respondents (a statistically significant 
finding) prefer C-QoL in PTO H compared to 56% of respondents (not statistically significant) 
who prefer T-QoL in PTO F when the comparator in both pairings is EoL-QoL (S2). However, 
this finding is not replicated across PTOs E and G. In a direct comparison of non-EoL 
treatments (see Table 5, PTOs I and J), T-QoL is preferred to C-QoL which also goes against 
our predictions based on prospective QALY loss; these results are statistically significant.    
 
3.2.1 EoL-LE vs non-EoL health gains  
 
Our results suggest that non-EoL health gains are preferred to EoL-LE (see Table 4, PTOs A-
D). More than 60% of respondents prefer non-EoL health gains in PTOs A, B and D (these 
results are statistically significant) and median of ratios are >2 indicating at least double the 
amount of patients need to receive an EoL treatment to produce the same benefit as 1 
patient receiving a non-EoL treatment. For these same PTOs, ratio of means are not as 
pronounced but they are still >1 in favour of non-EoL health gains. PTO C also indicates a 
marginal preference for C-QoL (53%), although this result is not statistically significant and 
ratios are approaching 1. Across PTOs A-D, those preferring T-QoL and C-QoL have more 
extreme and stronger preferences. Approximately 51% of those preferring a non-EoL 
treatment have extreme preferences compared to about 30% of those who prefer an EoL 
treatment (PTOs A-D). Also the average point of indifference for participants who prefer a 
non-EoL treatment (100X=No.Y(mean)) is lower than the equivalent for those who prefer a 
EoL-LE treatment (No.X(mean)=100Y), indicating participants who prefer non-EoL 
treatments have stronger preferences. For example, in PTO A 30 patients receiving EoL-LE 
(S7) produce the same benefit as 100 patients receiving T-QoL (S3), while 18 patients 
receiving T-QoL (S3) produce the same benefit as 100 patients receiving EoL-LE (S7); this 
suggests those who prefer T-QoL have stronger preferences.  
 
3.2.2 EoL-QoL vs Non-EoL health gains  
 
Results from PTOs E-H (see Table 4) suggest that EoL-QoL health gains are not preferred to 
non-EoL health gains and that EoL-QoL health gains are more preferred when patients’ 
initial QoL is lower. Approximately 50% of respondents prefer EoL-QoL compared to T-QoL 
or C-QoL when the QoL health gain is from 30%-80% in all scenarios (see PTOs E and G). 
While a smaller proportion of respondents (approximately 42%) prefer EoL-QoL compared 
to T-QoL or C-QoL when the QoL health gain is from 50%-100% in all scenarios (see PTOs F 
and H); however, this finding is only statistically significant in PTO H. Median of ratios are 
equivalent (1) when initial QoL is 30%, while they are around 2, indicating a preference for 
non-EoL treatments, when initial QoL is 50%. Ratio of means are not as pronounced but 
they are still higher when initial QoL is 50%. Those respondents preferring T-QoL or C-QoL 
have stronger and more extreme preferences; initial QoL does not seem to affect these 
results.   
 
3.3 Are preferences for EoL treatments contingent upon the type of health gain i.e. life 
expectancy versus quality of life? 
 
Overall, our results suggest that QoL improvements are preferred to life extensions (see 
Tables 4 and 5). Between-subject PTO comparisons (see PTOs A-H) show a lower percentage 
of respondents prefer EoL-LE treatments when compared to non-EoL treatments (T-QoL and 
C-QoL) than when EoL-QoL treatments are compared to the same non-EoL treatments. For 
example, when the comparator in each PTO is T-QoL (S3) 38% of respondents prefer EoL-LE 
(S7) in PTO A compared to 49% of respondents who prefer EoL-QoL (S1) in PTO E.  Ratios are 
generally closer to 1 when EoL-QoL scenarios are compared to non-EoL scenarios (PTOs E-H) 
than when EoL-LE scenarios are the comparator (PTOs A-D).  
 
Within-subject PTO comparisons indicate that when choosing between different EoL health 
gains respondents may prefer options that result in greater QoL improvements (see Table 5, 
PTO K and L). 68% of respondents prefer EoL-QoL when compared to EoL-LE (PTO K), this 
result is statistically significant. While the results of PTO L are not statistically significant, 
54% of respondents prefer the treatment providing a larger QoL health gain and shorter life 
extension (S8) compared to the smaller QoL health gain and longer life extension (S7). 
Although strength of preferences and extreme preferences are broadly equivalent for these 
two pairings, median of ratios and ratio of means indicate >1 patients have to receive life 
extending health gains (S7) to produce the same benefit as one patient receiving EoL-QoL 





Overall, the results of this study provide little evidence to suggest that the severity of the 
non-EoL comparator scenario plays a role in the value assigned to EoL treatments. 
Respondents do not appear to have a preference for EoL over non-EoL health gains; and 
there is some indication that non-EoL health gains are preferred, particularly when 
compared to EoL-LE health gains. Within EoL scenarios, our results suggest that QoL 
improvements are preferred to life extensions. 
 
The results of our study have similarities and differences with Pinto-Prades et al. (2014), on 
which this study builds that warrant discussion. Our study and Pinto-Prades et al. (2014) 
used similar scenarios to examine preferences for EoL-LE vs. T-QoL (PTO A), EoL-QoL vs. T-
QoL (PTO E) and EoL-LE vs. EoL-QoL (PTO K). Regarding EoL vs. T-QoL health gains (PTO A 
and E), Pinto-Prades et al.’s (2014) findings indicate a preference for EoL health gains while 
our results suggest T-QoL is preferred when the comparator is EoL-LE and preferences for 
EoL-QoL and T-QoL are broadly equivalent. Both studies find that QoL health gains are 
preferred to life extending health gains at the EoL (PTO K). The difference in the value of EoL 
health gains when compared to T-QoL could be due to the different locations in which the 
studies were undertaken – Spain and Scotland – or, more likely, related to issues within the 
design of our scenarios. While our scenarios were broadly similar to those used in Pinto-
Prades et al. (2014) they differed in relation to the description of the initial health states. As 
shown in Figure 1, our scenarios are presented in terms of current treatment and a potential 
new treatment meaning that even if the new treatment is not funded patients will receive 
the current treatment. Whereas, in Pinto-Prades et al. (2014) only those with a temporary 
condition receive an initial treatment, equivalent to our current treatment; the EoL 
scenarios are initially presented without treatment. Thus it is possible that EoL health gains 
are preferred in Pinto-Prades et al. (2014) due to participants feeling the need to provide 
some treatment at the EoL whereas this rationale is not as strong in our study as all patients 
will receive an initial treatment. Further support for differences in access to treatment 
affecting preferences is provided by a recent study by Hansen and Kjær (2019). This study 
also uses scenarios based on Pinto-Prades et al. (2014) but as with our study, scenarios are 
presented in terms of current treatment and a potential new treatment and their results 
suggest a preference for health gains for temporary conditions over EoL health gains.  
 
While Pinto-Prades et al. (2014) found a preference for EoL health gains, there is also 
evidence of preference heterogeneity; one group who strongly value EoL health gains, 
particularly short life extensions, and another group who place no or little value on these 
health gains. In our study there is also evidence of different groups with distinct views and 
within the wider literature, evidence is accumulating around plurality in preferences and 
views in relation to EoL (Hansen and Kjær, 2019; Mason et al., 2018; McHugh et al., 2015; 
McHugh et al., 2018; Pennington et al., 2015; Shah et al., 2015). Importantly, the results of 
this study and Pinto-Prades et al. (2014) suggest that a substantial proportion of 
respondents have lexicographic preferences, namely, that the treatment they prefer (EoL or 
non-EoL), should be given absolute priority in relation to the comparator. In our study this is 
indicated by respondents not making trade-offs e.g. stating 1 non-EoL=100 EoL and vice 
versa, approximately 42% of the PTO questions were answered in this way. The reasons for 
these views are not clear, as the CAPI survey did not incorporate qualitative work, after the 
pilot phase. However, in-depth work on societal views around EoL by McHugh et al. (2015) 
suggests EoL treatments may not be valued by some if the health gain is not viewed as 
substantial while others will view (even short) health gains at the EoL as important if they 
help patients to prepare for a good death. These lexicographic preferences raise interesting 
methodological and policy questions. Stated preference approaches ask respondents to 
make trade-offs and then data is aggregated, typically, using the mean. While aggregation of 
PTO data uses median of ratios and ratio of means, it is not clear to what extent it is 
theoretically correct to aggregate preferences that are lexicographic, as indicated by 
respondents’ refusal to make trade-offs. Relatedly, such preferences present a challenge for 
policymakers as they indicate that members of the public have entrenched points of view 
and are not willing to compromise. This makes the possibility of finding common ground 
unlikely and raises the probability of one societal group finding that their views are not 
represented in policy. This does provide an interesting avenue for future research around 
what should be done when people hold strongly, opposing views.  
 
We extended Pinto Prades et al. (2014) by including new chronic scenarios (C-QoL) to 
examine whether the severity, in terms of prospective QALY loss, of the non-EoL 
comparator scenario affects the relative value of EoL QALYs. While our results provided little 
evidence that the severity of the non-EoL scenarios influences preferences, what was 
unexpected was the value respondents assigned to T-QoL health gains, particularly as the 
literature suggests the most severely ill tend to be prioritised (Gu et al., 2015; Nord & 
Johansen, 2014; Shah, 2009; Whitty et al., 2014). T-QoL may have found support as it 
enables patients to avoid most (S3) or the full effects (S5) of their illness and so lead 
(relatively) normal lives. While C-QoL may not have found as much support as expected if 
respondents saw little value in only temporarily postponing the effects of an illness that will 
occur anyway. We know from piloting that respondents used both explanations but also 
that the T-QoL scenario was viewed as patients recovering anyway and so was not as 
valued. Unfortunately, the design of the main survey meant qualitative data was not 
collected alongside preferences with results suggesting respondents viewed T-QoL in a more 
favourable light.  
 
We also built on Pinto-Prades et al. (2014) by replicating the same comparisons using 
different scenarios. For example, QoL health gains in EoL-QoL, T-QoL and C-QoL were from 
30% to 80% and from 50% to 100%, whereas in Pinto-Prades et al. (2014) only a QoL health 
gain of 30% to 80% was utilised. When our comparisons were between EoL-QoL and non-
EoL treatments more support was found for EoL-QoL when initial QoL was 30% as opposed 
to 50%. This could suggest that EoL-QoL treatments receive more support when viewed as a 
way to provide patients with a good death if terminally ill patients initial QoL is considered 
to be low. However, our survey design only enabled between-subject comparisons as 
opposed to within subject-comparisons and our design did not enable us to make similar 
comparisons for EoL-LE vs. non-EoL health gains. Future work examining whether there is a 
threshold, in terms of initial QoL, at which respondents switch their preferences would help 
us to better understand respondents’ preferences for EoL health gains.   
 
The results of this study add to a growing subset of studies, including Pinto-Prades et al. 
(2014), which question whether life extensions are preferred to QoL improvements at the 
EoL (Hansen and Kjær, 2019; McHugh et al., 2018; Shah et al., 2014). So far only Shah et al. 
(2015) have found that life extensions are preferred. Although the evidence base remains 
equivocal as to whether EoL health gains are preferred to non-EoL health gains, the results 
of this study and others challenges current EoL policy by NICE and the Scottish Medicine 
Consortium (SMC) which give additional weight to EoL health gains. While SMC will consider 
QoL improvements, as well as other benefits, in their evaluation of EoL medicines that do 
not meet standard cost-effectiveness thresholds (SMC, 2016), it is unclear why NICE’s EoL 
policy only gives additional weight to life extending health gains.    
 
4.1.  Limitations 
 
This study has a number of limitations. Firstly, data collected via CAPI devices on a relatively 
large sample precluded the generation of qualitative data. This meant we were unable to 
explore how scenarios, including QoL percentages, were interpreted (beyond the initial pilot 
work) or the reasons for respondents’ preferences. Secondly, a large proportion of 
respondents appear to have extreme preferences as they refuse to make trade-offs. This 
could indicate that respondents either did not understand the task or that the task poorly 
captured their preferences. While some kind of misunderstanding may have contributed to 
this result we do not believe that extreme preferences are an artefact of the method. As 
noted previously, other EoL studies have found evidence of extreme preferences; 
importantly, this is not restricted to PTO studies as similar results have also been observed 
in WTP studies (Pinto-Prades et al., 2014; Pennington et al., 2015). Moreover, there is 
evidence of extreme preferences in other, non-EoL, PTO studies. For example, in Pinto-
Prades and Lopez-Nicolás (1998), respondents only had extreme preferences when the two 
outcomes seemed to be very different: saving 10 children’s lives vs. relieving mild health 
problems of a larger number of people. One way to understand the extreme preferences 
found in EoL studies and in Pinto-Prades and Lopez-Nicolás (1998) is that when people are 
very emotional about one issue whether that is children’s lives or people with a terminal 
illness System 1 thinking (from dual process theory) takes priority (Stanovich & West, 2000). 
Kahneman (2011) describes that when this happens respondents are more likely to 
substitute an easier heuristic question for the target question and to make a basic 
assessment. Thus respondents who feel an emotional response to EoL questions may 
choose not to make a trade-off as they either view providing a short life extension in bad 
health as absurd or believe that everything possible should be done for those with a 
terminal condition. Future research which explicitly tests this hypothesis would help to 
enhance our understanding of EoL preferences. Lastly, our respondents were quota sampled 
across Scotland rather than the UK. While it is possible that English, Welsh or Northern Irish 
respondents could have different EoL preferences to Scottish respondents, the EoL Q2S (Q 
methodology-based survey design) study which investigated societal perspectives across the 
UK gave no indication that there were between country differences (Mason et al., 2018).  
 
5. Conclusion  
 
This study has cast doubt on whether the comparator’s severity in terms of prospective 
QALY loss helps to explain the mixed findings in the EoL literature. Importantly for policy, 
our results suggest that when thinking as a social decision maker there is no clear 
preference for EoL (particularly life extending) health gains which raises questions regarding 
the policies currently used by NICE and to some extent SMC. Future work would benefit 
from more in-depth exploration of preferences that includes a significant qualitative 
component with a smaller sample of respondents to explore whether there is a threshold, in 
terms of initial QoL, at which respondents’ switch their preferences and the rationales given 
for the choice of treatments.  
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Appendix 1: Health Scenario Diagrams 
 
Notes on Appendix 1 
 
 The same scale is used for quality of life percentages (vertical axis) throughout all 
diagrams. The axis for quality of life on the programmed version stops at 100% 
 The same scale is used for life expectancy (horizontal axis) throughout.  
 The area marked HG is always the same size. While dimensions differ for S8 
(80% for 7 months) compared to the other scenarios (50% for 12 months) the 
size is broadly equivalent. 
 A version of the text underneath each health scenario is used in our WTP and PTO 
questions.   
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Patient X is diagnosed with a terminal illness. Doctors tell Patient X that with current 




 The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will improve Patient X’s quality of life from 30% to 80% for 12 months.  























 Spends one year in 30% health then dies 
 New treatment improves health from 30% to 80% for one year 
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Patient X is diagnosed with a terminal illness. Doctors tell Patient X that with current 






The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will improve Patient X’s quality of life from 50% to 100% for 12 months. 
























 Spends one year in 50% health then dies 
 New treatment improves health from 50% to full health for one year 








































Patient X is diagnosed with a temporary illness. Doctors tell Patient X that with 
current treatment Patient X will have a quality of life of 30% for 12 months. After 12 
months Patient X will return to full health.        
 
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will improve Patient X’s quality of life from 30% to 80% for 12 months. 
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Patient X is diagnosed with a chronic illness. Doctors tell Patient X that with current 
treatment Patient X will have a quality of life of 30% for the foreseeable future.    
 
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment:  
 Will improve Patient X’s quality of life from 30% to 80% for 12 months.  






















- Illness lasts for foreseeable future  
- New treatment improves health from 30% to 80% for one year 
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Patient X is diagnosed with a temporary illness. Doctors tell Patient X that with 
current treatment Patient X will have a quality of life of 50% for 12 months. After 12 
months Patient X will return to full health.    
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will improve Patient X’s quality of life from 50% to 100% for 12 months. 





















 Effects of illness last one year 
 New treatment improves health from 50% to full health for one year 
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Patient X is diagnosed with a chronic illness. Doctors tell Patient X that with current 
treatment Patient X will have a quality of life of 50% for the foreseeable future.   
 
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will improve Patient X’s quality of life from 50% to 100% for 12 months. 
























 Effects of illness last for foreseeable future  
 New treatment improves health from 50% to full health for one year 
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Patient X is diagnosed with a terminal illness. Doctors tell Patient X that with current 
treatment Patient X will live for another few weeks with Patient X’s health getting 
worse before dying.  
 
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will extend Patient X’s life by 12 months during which Patient X’s quality of life 
will be 50%. 






















































 Patient’s health gets worse over a few weeks & then he/she dies 
 New treatment extends life for seven months in 80% health 









































Patient X is diagnosed with a terminal illness. Doctors tell Patient X that with current 
treatment Patient X will live for another few weeks with Patient X’s health getting 
worse before dying.   
 
 
The doctor tells Patient X that a new treatment has become available. This new 
treatment: 
 Will extend Patient X’s life by 7 months during which Patient X’s quality of life will 
be 80%.  
 After 7 months Patient X will still die.     
 
Appendix 2: PTO Example Question – Scenario 2 vs. Scenario 5 
 
*A version of this PTO question was programmed for the CAPI* 
**Red text shows programming notes** 
Introduction  
The NHS has a fixed, additional budget available to fund new treatments. Imagine that two new treatments – Treatment A and Treatment B – 
are available that cost the same amount of money. Only one treatment type can be provided (funding cannot be split between the two 
treatments). You will see questions that ask you to choose between providing Treatment A or Treatment B. Descriptions of the treatments 

























Patients have been diagnosed with a terminal illness and 
are told that with current treatment they will live for 12 
months in a quality of life of 50% before dying. 
 
 New Treatment A: 
 Will improve their quality of life from 50% to 100% for 
12 months. 
 After this year they will still die. 
 
 
Patients have been diagnosed with a temporary illness and are 
told that with current treatment they will have a quality of life 




New Treatment B: 
 Will improve their quality of life from 50% to 100% for 12 
months. 























 Spends on  year in 50% health en dies 
 New treatment improves health from 50% to full health for one year 





























 Effects of illness last one year 
 New treatment improves health from 50% to full health for one year 










 12 mths 
Question 1 
 

























































Patients have been diagnosed with a terminal illness and 
are told that with current treatment they will live for 12 
months in a quality of life of 50% before dying. 
 
 
New Treatment A: 
 Will improve their quality of life from 50% to 100% for 
12 months. 
 After this year they will still die. 
 
 
Patients have been diagnosed with a temporary illness 
and are told that with current treatment they will have 
a quality of life of 50% for 12 months. After 12 months 
they will return to full health.  
 
 
New Treatment B: 
 Will improve their quality of life from 50% to 100% for 
12 months. 























 Spends one year in 50% health then dies 
 New treatment improves health from 50% to full health for one year 





























 Effects of illness last one year 
 New treatment improves health fro  50% to full health for one year 
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Question 2 
 
Now imagine that, if funded, Treatment A can treat 50 patients and Treatment B can treat 























































Patients have been diagnosed with a terminal illness and 
are told that with current treatment they will live for 12 
months in a quality of life of 50% before dying. 
 
 
New Treatment A: 
 Will improve their quality of life from 50% to 100% for 
12 months. 
 After this year they will still die. 
 
 
Patients have been diagnosed with a temporary illness 
and are told that with current treatment they will have 
a quality of life of 50% for 12 months. After 12 months 
they will return to full health.  
 
 
New Treatment B: 
 Will improve their quality of life from 50% to 100% for 
12 months. 























 Spends one year in 50% health then dies 
 New treatment improves health from 50% to full health for one year 




























 Effects of illness last one year 
 New treatment improves health from 50% to full health for one year 
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Question 3 
 
Now imagine that, if funded, Treatment A can treat 75 patients and Treatment B can treat 







































[Choice in Question 4 depends on answer to Question 3. Subsequent questions follow the 
same format until the point of indifference is reached.] 
 
 










Patients have been diagnosed with a terminal illness and 
are told that with current treatment they will live for 12 
months in a quality of life of 50% before dying. 
 
 
New Treatment A: 
 Will improve their quality of life from 50% to 100% for 
12 months. 
 After this year they will still die. 
 
 
Patients have been diagnosed with a temporary illness 
and are told that with current treatment they will have 
a quality of life of 50% for 12 months. After 12 months 
they will return to full health.  
 
 
New Treatment B: 
 Will improve their quality of life from 50% to 100% for 
12 months. 























 Spends one year in 50% health then dies 
 New treatment improves health from 50% to full health for one year 





























 Effects of illness last one year 
 New treatment improves health from 50% to full health for one year 
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Appendix 3: Script for animation  
 
Note on Appendix 3 
 Voiceover to stress words in bold 
 
1. The National Health Service is funded directly by the public.  
2. The NHS spends its budget on many things, including doctors, nurses, beds, new 
drugs and treatments.  
3. Although the health service budget is very big, it is still a fixed amount. There is 
never enough money to do everything we want.  
4. Of course, the NHS budget could grow in the future.  
5. But this research is about the money the health service has now, and the best way 
to spend it.  
6. Because the budget is fixed, difficult decisions have to be made about how to 
spend NHS money.  
7. When the NHS provides a service, the public benefits. But the public will not benefit 
if that service is not funded.  
8. Because of this, and because the public pays for the NHS through its taxes, it is 
important that decisions on how to spend NHS money take into account the views of 
the public.  
9. For example, thinking generally about all NHS patients, should we concentrate our 
funding on the treatment of people who are most severely ill? Or perhaps we should 
focus our spending on treatments that give people a better quality of life? Or should 
we prioritise the funding of treatments that help people to live longer?  
10. These are difficult decisions to make, and there are no right or wrong answers.  
11. As a member of the public, we need to know your views on this important topic.  
 
  
Appendix 4: Example of PTO ratio calculations   
 
Calculation of the ‘ratio of means’ involves assigning a value of 1 to the most-favoured 
treatment in each individual choice, with the less-favoured treatment receiving a value 
equal to the number of patients in the most-favoured group divided by the number of 
patients in the less-favoured group. Means across all respondents for each treatment (X 
and Y) are then calculated and then ratio of means determined. ‘Median of ratios’ 
comprises calculating ratios, X/Y (alternatively Y/X could be utilised), for each individual 
respondent and then taking the median of ratios across all respondents.  These 





Ratio of Means (RoM) 
Median of ratios 
X Y X based Y based 
1 25 100 1.00 0.25 0.25 4.00 
2 10 100 1.00 0.10 0.10 10.00 
3 5 100 1.00 0.05 0.05 20.00 
4 100 5 0.05 1.00 20.00 0.05 
5 100 10 0.10 1.00 10.00 0.10 
   
Mean=0.63 Mean=0.48     
   
RoM (X/Y) 1.31 0.25 4.00 
   
RoM (Y/X) 0.76 
  (*) Number (Ni) of patients X(Y) which are considered equivalent to 100 patients Y(X). 
 
 
 
 
